Research programme: inflammation therapy - Nycomed/Pharmacopeia Drug Discovery
Latest Information Update: 05 Jun 2007
Price :
$50 *
At a glance
- Originator Nycomed; Pharmacopeia Drug Discovery
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 31 Dec 2003 Preclinical trials in Inflammation in Germany (unspecified route)